PERCEPTIVE ADVISORS LLC

October 14, 2026

Stifel initiates Immatics coverage with $15 price target. Stifel began covering Immatics with a Buy rating and a $15 price target, joining a broader wave of new analyst initiations. This new perspective adds to the existing analyst consensus, which currently averages $17.63. The stock is currently trading near its 52-week low, with an RSI of 27.8 indicating oversold conditions.

September 25, 2026

Freenome highlights CRC screening market potential. Freenome is emphasizing the large addressable market for its colorectal cancer screening test, noting it can reach 50 million patients while facing less direct competition. This narrative aims to support the company's growth outlook as the stock trades near its 52-week high range.

October 13, 2026

UBS initiates coverage on Kardigan with $25 price target. UBS has started tracking Kardigan Inc. and set a price target of $25. This new analyst view is notable because it sits below the current average analyst target of $42.25. The stock is currently trading near its support level, which may reflect the mixed sentiment from this new coverage.

September 25, 2026

Goldman Sachs initiates MeiraGTx coverage with Neutral rating. Goldman Sachs has started covering MeiraGTx, assigning a Neutral rating and a price target of $16. This new analyst view comes as the company also appointed Alan M. Sebulsky to its board of directors. The stock is currently trading near its 52-week low, providing context for the firm's initial assessment.

September 29, 2026

LeonaBio appears among health‑care stocks moving intraday. LeonaBio was listed among twelve health‑care stocks that showed notable price movement on Monday and again on Friday, according to Benzinga. The mentions suggest the stock experienced intraday volatility during those sessions. With the RSI currently low and the price near a recent support level, the recent activity aligns with a broader sector‑wide movement.

September 27, 2026

OBIO Shares Rise 5.2% Amid Positive Momentum. Orchestra BioMed Holdings (OBIO) shares recently increased by 5.2%, a move that some observers see as a sign of strengthening momentum. The stock currently trades within its 52-week range of $2.20 to $6.48. Analysts maintain an average price target of $12.14, suggesting a significant gap between the current market price and professional estimates.

October 15, 2026

Acrivon Therapeutics noted among health‑care stocks moving in after‑market. Acrivon Therapeutics (ACRV) was included in a Benzinga roundup of twelve health‑care stocks that showed price movement during Wednesday’s after‑market session. The mention signals recent trading activity after regular hours. The stock is currently near its 52‑week low and its RSI is below 40, suggesting limited momentum.

September 28, 2026

Biotech Sector News Dominates; No Specific ALDX Updates. Recent news coverage focuses on clinical trial results for other biotechnology companies, such as ACAD and Vertex, rather than Aldeyra Therapeutics. There are no new company-specific announcements or trial updates for ALDX in the provided reports. The stock is currently trading near its 52-week low, reflecting broader sector sentiment rather than isolated corporate news.

October 16, 2026

SLDB Featured in After-Market Movers List. Solid Biosciences was included in a Benzinga list of healthcare stocks moving in Friday's after-market session. The stock is currently trading near its 52-week low, with an RSI of 20.5 indicating oversold conditions. Analysts maintain an average price target of $18.62, which is significantly higher than the current trading range.

September 30, 2026

Verrica to present new YCANTH data at dermatology conferences. Verrica Pharmaceuticals announced it will present new data analysis for its drug YCANTH at two upcoming dermatology conferences. This event allows the company to share recent findings with medical professionals, which is a standard step in communicating clinical progress for its products. The stock currently trades within a wide 52-week range, reflecting the uncertainty often associated with clinical data releases.

September 29, 2026

Roth Capital initiates coverage on NAUT with $3.50 target. Roth Capital began tracking Nautilus Biotechnology with a Buy rating and a price target of $3.50. This new analyst note adds to the current consensus, where the average target from two analysts is $4.00. The stock is currently trading within its 52-week range of $0.72 to $4.31.

October 13, 2026

ADMA Biologics Draws Investor Attention Amid Market Decline. Recent reports indicate that ADMA Biologics is attracting investor attention and showing relative strength while the broader market declines. Analysts have expressed optimism, with an average price target of $17.00, which is well above the current trading range. This suggests that some market participants view the stock as undervalued relative to its long-term potential, despite recent volatility.